Biohealthmatics.com Syndicated Biomedical Informatics News

BioMarin shares rise on Citi upgrade to 'Buy' (AP)

Sat, 22 Nov 2008 05:46:20 GMT

Shares of BioMarin Pharmaceutical Inc. rose Friday after Citi upgraded the stock based on the sales potential for its three approved treatments, its early-stage development products and healthy cash

Abbott settles finofibrate claims

Sat, 22 Nov 2008 02:21:03 GMT

Abbott Laboratories Inc. disclosed in a regulatory filing that it has agreed to pay $184 million to settle litigation involving the formulation and price of its Tricor cholesterol

Transgene?s TG1042 meets primary end point in step one of cutaneous B-cell lymphoma Phase II trial

Fri, 21 Nov 2008 21:06:00 GMT

? Transgene (Euronext Paris: FR0005175080) today announced that the primary end point has been met in the first step of the ongoing Phase II trial with its immunotherapy product TG1042 (Ad-IFN?) in patients with relapsing primary cutaneous

GenoMed Joins StockProfile.com, Adds Dedicated Patient Website for Greater Visibility

Fri, 21 Nov 2008 21:06:00 GMT

? GenoMed, Inc. (Other OTC: GMED.PK), today announced that it has joined www. StockProfile.com, a customized web-based platform showcasing emerging growth stocks. StockProfile.com provides the investing public with a unique information portal

Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference

Fri, 21 Nov 2008 21:37:00 GMT

LOVELAND, Colo., Nov. 21 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA - News) today announced it will present at the New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008 at

More biotech applications being pushed

Fri, 21 Nov 2008 21:46:00 GMT

AN official of the Department of Agriculture wants to reorient Philippine agriculture from a resource-based sector to a technology-based sector that would ensure farmers not only higher yields but also low production costs. Agriculture

Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference

Fri, 21 Nov 2008 21:47:00 GMT

LOVELAND, Colo., Nov. 21 LOVELAND, Colo., Nov. 21 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA) today announced it will present at the New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference on December

Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference

Fri, 21 Nov 2008 21:54:00 GMT

LOVELAND, Colo., Nov. 21 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA) today announced it will present at the New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008 at 1177 Avenue

Hana Biosciences Receives NASDAQ Notification

Fri, 21 Nov 2008 21:56:00 GMT

As provided in the NASDAQ rules, the Company has the opportunity to submit to NASDAQ a specific plan and timeline to achieve and sustain compliance. The Company intends to submit in a timely manner to the NASDAQ Staff a plan to regain compliance with

ImClone Systems Inc. (USA): Deletion

Fri, 21 Nov 2008 21:59:00 GMT

Subject to the completion of the cash tender offer of ImClone Systems Inc. (USA, constituent) by Eli Lilly & Co. (USA, constituent), FTSE announces the following changes: INDEXCHANGEEFFECTIVE FROM START OF TRADINGFTSE All-World IndexImClone Systems

Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteosarcoma

Fri, 21 Nov 2008 22:02:00 GMT

Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th

Hana Biosciences Receives NASDAQ Notification

Fri, 21 Nov 2008 22:03:00 GMT

Extract not

Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference

Fri, 21 Nov 2008 22:04:00 GMT

Hana Biosciences Receives NASDAQ Notification

Fri, 21 Nov 2008 22:04:00 GMT

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (NasdaqCM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, reported that it received a letter, dated November 19, 2008,

Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty...

Fri, 21 Nov 2008 22:08:00 GMT

Ice Age park? Scientists sequence mammoth genome

Fri, 21 Nov 2008 22:10:00 GMT

WASHINGTON: Scientists have sequenced the genome of the woolly mammoth of the Ice Age, bringing to reality the possibility of an Ice Age park in the lines of the fictional Jurassic Park of Michael Crichton. With four billlion DNA bases, the

Hana Biosciences receives Nasdaq letter for non-compliance with minimum stockholders' equity requirement - Quick Facts

Fri, 21 Nov 2008 22:11:00 GMT

Hana Biosciences receives Nasdaq letter for non-compliance with minimum stockholders' equity requirement - Quick Facts (RTTNews) - Hana Biosciences (HNAB: News ) said that it received a letter, dated November 19, from the Listing

Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference

Fri, 21 Nov 2008 22:21:00 GMT

LOVELAND, Colo., Nov. 21 /PRNewswire-FirstCall/ -- Heska Corporation (HSKA) today announced it will present at the New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008 at 1177 Avenue of

Hana Biosciences Receives NASDAQ Notification

Fri, 21 Nov 2008 22:26:00 GMT

Thomson Reuters 2008 All rights

Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference

Fri, 21 Nov 2008 22:51:00 GMT

/PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences will be presenting at the 20th Annual Piper Jaffray Health Care Conference in New York. The

Incyte to Present at the 20th Annual Piper Jaffray Health Care Conference

Fri, 21 Nov 2008 22:51:00 GMT

- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 20 Paul Friedman, M.D., president and chief executive officer of Incyte, will provide an overview of the company and discuss its most advanced drug discovery and

More biotech bankruptcies on the horizon

Fri, 21 Nov 2008 22:52:00 GMT

The biotech bankruptcy used to be a rare animal. Struggling small developers were usually saved by deals or mergers with bigger, healthier drug companies. But the ongoing economic crisis had made a once-uncommon occurrence a very real possibility

Bioengineering

Fri, 21 Nov 2008 23:11:00 GMT

Select a category: Select category Bio-Sensors Biological Warfare Brain chips/computer interface Cellular Reprogramming Computers and Medicine Cryonics Drug Delivery Technology Gene Therapy Genetic Engineering Genetics Human Enhancement

Biotech firms face bitter pill as money dries up

Fri, 21 Nov 2008 23:15:00 GMT

The global economic crisis has cut funding for biotechnology companies to the lowest level in a decade, triggering bank-ruptcies and threatening development of drugs based on biomedical breakthroughs. In the past month, at least five

The search for genome 'dark matter' moves closer - Premium content

Sat, 22 Nov 2008 00:00:00 GMT

Extract not

Rescinding Bush's stem cell limits creates biotech glee

Sat, 22 Nov 2008 00:03:00 GMT

Nov. 21--President-elect Barack Obama should rescind President Bush's limits on stem cell research, said Jim Hardy, president and CEO of Gahaga Biosciences Inc. in Frederick. Bush's decision not to fund stem cell research is keeping the U.S. behind

Hana Biosciences faces Nasdaq delisiting

Sat, 22 Nov 2008 00:16:00 GMT

The stock of the South San Francisco cancer drug developer (NASDAQ: HNAB) does not meet the exchanges rule that require a minimum of $2.5 million in stockholder equity. It has until Dec. 4 to provide a plan for complying with the markets rules or

Genetically engineered insects may save the Florida orange

Sat, 22 Nov 2008 00:21:00 GMT

The disease that has been ravaging Florida?s orange groves may soon be put to an end by genetically engineered predators. The Asian Citrix Psyllid has spread the devastating ?greening disease? across Florida citrus groves since its

Hana Biosciences Receives NASDAQ Notification

Sat, 22 Nov 2008 01:11:00 GMT

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences , a biopharmaceutical company focused on strengthening the foundation of cancer care, reported that it received a letter, dated November 19, 2008, from the

Medco sees powerful opportunity in generic biotech

Sat, 22 Nov 2008 01:42:00 GMT

Extract not

Cougar Biotechnology initiates enrollment in Phase I/II breast cancer study

Sat, 22 Nov 2008 01:44:00 GMT

Cougar Biotechnology has enrolled the first patient in a Phase I/II clinical trial of the company's drug candidate CB7630, an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced breast

::: Transgene's TG1042 meets primary end point in step one of cutaneous B-cell lymphoma Phase II trial

Sat, 22 Nov 2008 01:52:00 GMT

NPS Pharmaceuticals to Present at Piper Jaffray Health Care Conference (Business Wire)

Sat, 22 Nov 2008 01:45:00 GMT

BEDMINSTER, N.J.----NPS Pharmaceuticals, Inc. announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 3, 2008 at 12:00

BioTime Inc. Announces Third Quarter 2008 Financial Results (Business Wire)

Sat, 22 Nov 2008 01:47:00 GMT

ALAMEDA, Calif.----On November 19, 2008 BioTime, Inc. reported financial results for the quarter ended September 30,

Dyax drug candidate gets FDA priority review (AP)

Sat, 22 Nov 2008 01:58:15 GMT

Dyax Corp. said Friday the Food and Drug Administration is giving priority review to the biotechnology company's developing treatment for a genetic condition that can lead to dangerous

Wyeth Names Kamarck to Run Factories (at The Wall Street Journal Online)

Sat, 22 Nov 2008 02:11:00 GMT

Exelixis Announces December 2 Webcast of Presentation at the Piper Jaffray 20th Annual Health Care Conference (Business Wire)

Sat, 22 Nov 2008 02:15:00 GMT

SOUTH SAN FRANCISCO, Calif.----Exelixis, Inc. announced today that George A. Scangos, PhD, President and Chief Executive Officer of Exelixis, will present at the Piper Jaffray 20th Annual Health Care Conference at 11:00

Coughing Is Bad for Amgen's Health (at Motley Fool)

Sat, 22 Nov 2008 02:20:31 GMT

Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference (PR Newswire)

Sat, 22 Nov 2008 02:30:00 GMT

Heska Corporation today announced it will present at the New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008 at 1177 Avenue of the Americas, 2nd Floor in New York,

BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer (PR Newswire)

Sat, 22 Nov 2008 02:30:00 GMT

BioMarin Pharmaceutical Inc. today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27,

[$$] Treasury Pick Soothes Volatility (at RealMoney by TheStreet.com)

Sat, 22 Nov 2008 02:37:58 GMT

Gilead Sciences, Microsoft: Money Flow Leaders (GILD, MSFT) (at The Wall Street Journal Online)

Sat, 22 Nov 2008 02:39:41 GMT

Gilead Sciences, Microsoft: Money Flow Leaders Markets Data Center: Money Flow

Hana Biosciences Receives NASDAQ Notification (GlobeNewswire)

Sat, 22 Nov 2008 02:47:26 GMT

Final Glance: Biotechnology companies (AP)

Sat, 22 Nov 2008 04:14:16 GMT

Oppenheimer takes cautious view on ViroPharma (AP)

Sat, 22 Nov 2008 05:31:35 GMT

Oppenheimer & Co. started coverage on ViroPharma Inc. Friday with a "Perform" rating, taking a cautious position on the company over concern that competitors for its core products are closer to reaching the

Company Profile for Life Technologies Corporation

Fri, 21 Nov 2008 00:00:00 GMT

Invitrogen and Applied Biosystems Complete Merger

Fri, 21 Nov 2008 00:00:00 GMT

EnteroMedics Announces $20 Million Debt Financing

Fri, 21 Nov 2008 00:00:00 GMT

CDC Monitors Shortage of Hib Vaccine

Fri, 21 Nov 2008 22:06:43 GMT

U.S. health officials said Thursday that a shortage of vaccine is leading them to monitor Hib infections, one of the most important causes of bacterial illness in young

American Diabetes Association: Real-Life Stories of Diabetes Success

Fri, 21 Nov 2008 21:48:00 GMT

ALEXANDRIA, VA (MARKET WIRE) How do you measure success? The December issue of Diabetes Forecast, the consumer magazine of the American Diabetes Association, features the personal triumphs of people with diabetes -- some of their stories may surprise you. Here are just a

Merck Adds to Biotech Center

Fri, 21 Nov 2008 16:51:00 GMT

Email This Page Share on LinkedIn Copyright Permissions Comment on This Story Custom Reprints Current Issue View Archives More Pharmaceuticals & Fine Chemicals SAFC: The Age of the Blockbuster Drug has â??Disappearedâ?? GSK to Shut

Gene Chips Accurately Detect Pneumonia in ICU Patients on Ventilators

Fri, 21 Nov 2008 17:03:00 GMT

Even seasoned doctors have a difficult time diagnosing pneumonia in hospitalized patients breathing with the assistance of a ventilator. That's because a patient's underlying illness often skews laboratory test results and masks pneumonia's

Amgen gets positive EU nod for blood-clot drug

Fri, 21 Nov 2008 17:39:00 GMT

NEW YORK - Shares of Amgen Inc. rose Friday after the company said a European advisory committee is in favor of approving the biotechnology company's drug Nplate, which treats a rare blood-clotting disorder. The stock rose $1.27, or 2.5 percent,

Medco sees powerful opportunity in generic biotech

Fri, 21 Nov 2008 18:07:00 GMT

By Lewis Krauskopf NEW YORK (Reuters) - More than $34 billion worth of biotechnology medicines could become available as generics in the United States between 2013-2017 if lawmakers approve a path for their approval, Medco Health Solutions Inc said

Australia's big hop into genomics

Fri, 21 Nov 2008 18:08:00 GMT

Extract not

Pahang Confident Biotechnology And ICT Will Bring High Returns

Fri, 21 Nov 2008 18:13:00 GMT

KUANTAN, Nov 21 (Bernama) -- Pahang Menteri Besar, Datuk Seri Adnan Yaakob, said the state is confident its involvement in biotechnology and information and communications technology (ICT) will bring in high income for the state. He said two

Fairfax, some other GM plants to take longer holiday shutdown

Fri, 21 Nov 2008 18:40:00 GMT

Extract not

JCR, Fuji Pharma To Enter Market For Generic Biotech Drugs

Fri, 21 Nov 2008 18:44:00 GMT

Extract not

FDA clears ImClone's BB50 production unit

Fri, 21 Nov 2008 18:50:00 GMT

Extract not

AnaSpec Signs Distribution Agreement with Shanghai Universal Biotech Company

Fri, 21 Nov 2008 19:01:00 GMT

Extract not

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 19:19:00 GMT

INDIANAPOLIS and New York, Nov. 21 (HSMN NewsFeed) -- Eli Lilly and Company (NYSE: LLY ) and ImClone Systems Incorporated (Nasdaq: IMCL ) today announced the successful completion of the previously announced tender offer by Lilly's

Whatever you do, don't mention GMOs

Fri, 21 Nov 2008 19:24:00 GMT

Extract not

Generic Biotech Drugs May Become Catalyst For Industry Shake-Up

Fri, 21 Nov 2008 19:50:00 GMT

Extract not

Precision Therapeutics Secures $43 Million in Venture Capital Funding

Fri, 21 Nov 2008 02:34:00 GMT

[NEWS] PITTSBURGH, Nov. 10 — Precision Therapeutics Inc., a leader in the development of predictive drug response tests, has secured $43 million in additional funding to expand the development and commercialization of ChemoFx®. ChemoFx is a diagnostic test that helps physicians select the most effective chemotherapeutic regimen for cancer patients.

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet ...

Fri, 21 Nov 2008 02:43:00 GMT

[NEWS] PHILADELPHIA, Nov. 20 —GlaxoSmithKline (NYSE: GSK) today announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA® (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue ...

Fri, 21 Nov 2008 05:49:00 GMT

[NEWS] SAN MARINO, Calif., Nov. 20 /PRNewswire/ — Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November

Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO

Fri, 21 Nov 2008 15:15:00 GMT

[NEWS] NEW YORK, Nov. 21 /PRNewswire-FirstCall/ — Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease released today the following Letter to Shareholders from Dr. Daniel Chain, its Chairman and CEO.

Huifeng Bio-Pharmaceutical (HFGB) Reports Record Sales and Net Income

Fri, 21 Nov 2008 17:30:00 GMT

[NEWS] XI'AN, China, Nov. 21 — Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, is pleased to announce record sales and earnings for the three and nine month periods ended September

CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in ...

Fri, 21 Nov 2008 17:30:00 GMT

[NEWS] MAIDENHEAD, England, November 21 — The European Committee for Medicinal Products for Human Use (CHMP) today announced its positive recommendation for the approval of Enbrel® (etanercept) as a treatment for children aged 8 years and over and adolescents with severe plaque

Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. ...

Fri, 21 Nov 2008 18:00:00 GMT

[NEWS] BOZEN, Italy, November 21 — Health Robotics today announced that it has signed a definitive agreement with Devon International Group (DIG) and its strategic partner ITOCHU International, Inc., whereby DIG and ITOCHU have acquired the exclusive rights to manufacture, market, sub-license, implement, interface, and support Health

Baxa Corporation Announces Co-Marketing Agreement With Industry Leaders Pharmacy OneSource, Inc ...

Fri, 21 Nov 2008 18:00:00 GMT

[NEWS] Announcing the collaboration of Baxa Corporation, ClinicalIQ LLC, and Pharmacy OneSource, Inc to bring greater understanding of, and compliance to, USP < 797 > for the healthcare industry. ENGLEWOOD, Colo., Nov. 21 — Baxa Corporation has teamed up with industry leaders ClinicalIQ, LLC and Pharmacy

Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income

Fri, 21 Nov 2008 18:01:00 GMT

[NEWS] LARGO, Fla., Nov. 21 /PRNewswire-FirstCall/ — Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the first quarter ended September 30, 2008 (FY2009). Net sales, excluding

NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology ...

Fri, 21 Nov 2008 18:40:00 GMT

[NEWS] LAWRENCE, Mass., Nov. 21 — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it ranked 14th on Deloitte's 2008 Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. Rankings are based

CTI chief learns hard lessons from merger (at FT.com)

Fri, 21 Nov 2008 22:15:22 GMT

The chief executive of Seattle-based Cell Therapeutics says he has learnt some tough lessons from his experience of integrating a pair of US and Italian biotechnology

BioMarin shares rise on Citi upgrade to 'Buy' (AP)

Fri, 21 Nov 2008 22:26:42 GMT

Shares of BioMarin Pharmaceutical Inc. rose Friday after Citi upgraded the stock based on the sales potential for its three approved treatments, its early-stage development products and healthy cash

Curtain Falls on ImClone Drama, as Lilly Completes Tender (at The Wall Street Journal Online)

Fri, 21 Nov 2008 23:12:00 GMT

Midday Glance: Biotechnology companies (AP)

Fri, 21 Nov 2008 23:30:54 GMT

Oppenheimer takes cautious view on ViroPharma (AP)

Fri, 21 Nov 2008 23:45:04 GMT

Pharmaceuticals Industry (Zacks.com)

Sat, 22 Nov 2008 01:25:54 GMT

Invitrogen and Applied Biosystems Complete Merger (Business Wire)

Sat, 22 Nov 2008 01:30:00 GMT

CARLSBAD, Calif.----Invitrogen Corporation and Applied Biosystems Inc. today announced the successful completion of their merger transaction. The new company will be named Life Technologies Corporation and will be traded on the NASDAQ Global Select Market under the ticker symbol "LIFE" beginning November 24,

Scripps research scientists identify blood component that turns bacteria virulent

Fri, 21 Nov 2008 00:00:00 GMT

Healthnostics Approves Reverse Stock Split

Fri, 21 Nov 2008 00:00:00 GMT

Red Mountain Pharmaceuticals Inc. Merges With Zalemark Inc.

Fri, 21 Nov 2008 00:00:00 GMT

Scientists Say HIV Testing Still Misses Many

Fri, 21 Nov 2008 17:56:09 GMT

HIV screening has become more routine, but scientists say people are still falling through the

Tecan: Tecan's Infinite(R) M1000 and Infinite F500 Multimode Readers Are Certified as DLReady(TM)

Fri, 21 Nov 2008 16:50:00 GMT

DURHAM, NC (MARKET WIRE) Tecan, a global leader in laboratory automation and detection, has been granted DLReady(TM) certification status for its high-end multimode readers Infinite(R) M1000 and Infinite F500, by Promega Corporation, USA, a provider of innovative solutions and technical support to the life sciences

Red Mountain Pharmaceuticals Inc.: Red Mountain Pharmaceuticals Inc. Merges With Zalemark Inc.

Fri, 21 Nov 2008 19:44:00 GMT

SHERMAN OAKS, CA and DALLAS, TX (MARKET WIRE) Charis Industries Co. (dba Red Mountain Pharmaceuticals Inc.) (RMPI) (PINKSHEETS: RMPI) has merged with Zalemark Inc. Zalemark (www.zalemark.com) is a leading jewelry branding, design, and manufacturing company headquartered in Sherman Oaks, California. Terms of the merger were not disclosed.

Research and Markets: Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics Focuses on Partnerships for Business, Product, Technology and Royalty Assets

Fri, 21 Nov 2008 13:57:00 GMT

- Research and Markets ( The Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter asset purchase deals. The report provides a detailed

Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America

Fri, 21 Nov 2008 13:58:00 GMT

/PRNewswire/ -- Cyntellect, a privately-held life sciences company leading the development and commercialization of live cell analysis and manipulation systems, announced today that it has appointed Andre Lubarsky as the Company's Director of Sales

Lilly completes tender offer for ImClone

Fri, 21 Nov 2008 14:03:00 GMT

NEW YORK (MarketWatch) -- Eli Lilly and Co. (LLY:LLYNews, chart, profile, moreLast: Delayed quote dataAnalyst Create alertInsider Discuss Financials Sponsored by:, , ) said Friday that it has successfully completed its tender offer for ImClone

`Unprecedented' Biotech Bankruptcies Erupt Amid Finance Crisis

Fri, 21 Nov 2008 14:10:00 GMT

In the past month, at least five biotechnology businesses have sought bankruptcy protection, according to company news releases, and others may be heading toward a similar fate. Those at highest risk have experimental compounds moving into costly

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 14:12:00 GMT

INDIANAPOLIS and New York, Nov. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (LLY) and ImClone Systems Incorporated (IMCL) today announced the successful completion of the previously announced tender offer by Lilly's wholly-owned

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 14:19:00 GMT

The depositary for the tender offer has advised Lilly and ImClone that, as of the expiration of the tender offer, approximately 85,401,945 shares (including 5,175,275 shares that were tendered pursuant to guaranteed delivery procedures) were

Patient makes good recovery after transplant of a bioengineered airway

Fri, 21 Nov 2008 14:22:00 GMT

Extract not

Study: N.C. leads in biosciences growth

Fri, 21 Nov 2008 14:22:00 GMT

According to a 133-page report produced by the Battelle Memorial Institutes Technology Partnership Practice, North Carolinas net job growth in the biosciences sector from 2001 to 2006 was 18.5 percent three times the rate nationwide. That growth rate

Amgen says Nplate Receives Positive Opinion for Marketing Authorisation in European Union - Quick Facts

Fri, 21 Nov 2008 14:24:00 GMT

Amgen Inc. (AMGN: News ) announced that the European Committee for Medicinal Products for Human Use, or CHMP, has issued a positive opinion recommending marketing authorisation for Nplate, or romiplostim, in the European Union. Nplate, a

Amgen, Takeda and Millennium suspend enrollment in Phase III lung cancer trial

Fri, 21 Nov 2008 14:29:00 GMT

Motesanib is part of a broad co-development program between Amgen and Takeda. The data monitoring committee(DMC) recommended that enrollment in the study, which allowed both squamous and non-squamous non-small cell lung cancer (NSCLC) patients,

Cougar Biotechnology initiates enrollment in Phase I/II breast cancer study

Fri, 21 Nov 2008 14:30:00 GMT

The Phase I/II trial is being conducted at The Institute of Cancer Research in London and managed by the Drug Development Office of Cancer Research UK, which is funding the trial. The Phase I/II clinical trial, which is open only to UK women, is an

Imclone Systems Rises In Pre-Market After Eli Lilly Completes Cash Tender Offer

Fri, 21 Nov 2008 14:30:00 GMT

Extract not

Amgen says CHMP recommends marketing approval for Nplate in European Union - Update

Fri, 21 Nov 2008 14:43:00 GMT

biotechnology company, Amgen, Inc. (AMGN: News ) said it received a positive opinion from the European Committee for Medicinal Products for Human Use, or CHMP, regarding the market authorization of Nplate in the European Union. Nplate, a

Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America

Fri, 21 Nov 2008 14:58:00 GMT

New hire brings over 20 years of commercial life sciences sales experience to Cyntellect SAN DIEGO, Nov. 21 /PRNewswire/ -- Cyntellect, a privately-held life sciences company leading the development and commercialization of live cell analysis

AnaSpec Signs Distribution Agreement with Shanghai Universal Biotech Company

Fri, 21 Nov 2008 15:13:00 GMT

SAN JOSE, Calif., Nov. 20, 2008--AnaSpec and Shanghai Universal Biotech Company today announced a non-exclusive distributor agreement that will allow Shanghai Universal Biotech Company to distribute AnaSpecs catalog and custom products throughout

Genentech Adds Onto Thursday's Steep Loss

Fri, 21 Nov 2008 15:14:00 GMT

Genentech (DNA: News ) has eased steadily throughout the first 40 minutes of trading. The stock is extending Thursday's loss and is at its lowest level since mid-October, down $2.86 at $70.17. by RTT Staff Writer For comments and feedback:

GMOs - Council Discussions - Genetically modified soya

Fri, 21 Nov 2008 15:14:00 GMT

Food Law News - EU - 2008 FSA Interested Parties Letter (ENF/E/08/072; NFAS 563), 10 November 2008 SUPPLEMENTS - Food Supplements: Opinion Issued by European Food Safety Authority on Six Nutrient Sources Containing Vanadium For previous news items

Moody's cuts Eli Lilly on ImClone acquisition

Fri, 21 Nov 2008 15:20:00 GMT

SAN FRANCISCO (MarketWatch) -- Moody's Investors Service on Friday downgraded Eli Lilly's (LLY:LLYNews, chart, profile, moreLast: Delayed quote dataAnalyst Create alertInsider Discuss Financials Sponsored by:, , ) long-term rating to A1 from Aa3

Biotech Executive John Collar Named Executive Director of the Colorado BioScience Association, Effective December 8

Fri, 21 Nov 2008 15:23:00 GMT

John Collar, Chief Operating Officer of Westminster-based Matrilinex, a start up mitochondrial DNA testing lab company, has been named Executive Director of the Colorado BioScience Association(CBSA), effective December 8, 2008. The announcement is

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 15:31:00 GMT

/PRNewswire-FirstCall/ -- Eli Lilly and Company and ImClone Systems Incorporated today announced the successful completion of the previously announced tender offer by Lilly's wholly-owned subsidiary, Alaska Acquisition Corporation, for all

Citi Maintains 'Buy' Rating on Amgen (AMGN), Adds Stock to Top Picks Live List

Fri, 21 Nov 2008 15:32:00 GMT

Citi maintains a 'Buy' rating on Amgen Inc (Nasdaq: AMGN), adds stock to Top Picks Live list. Price target $66. Citi analyst says, 'We are adding Amgen to Top Pick Live (TPL) as we anticipate a potential for attractive returns in 2009 in a very

Top Five Ways to Avoid GMOs in Your Food

Fri, 21 Nov 2008 15:43:00 GMT

America has one of the highest levels of GMOs in their food chain in the western world with up to 85 percent of its pre-packaged and processed foods coming from genetic engineering. (Natural News) Recent polls across the world have consistently

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 16:00:00 GMT

Eli Lilly buys majority of ImClone in tender offer

Fri, 21 Nov 2008 16:04:00 GMT

NEW YORK - Drug developer Eli Lilly & Co. said Friday it completed a tender offer worth about $6 billion for ImClone Systems Inc., marking Lilly's biggest buyout in the biotechnology industry. The company announced the $70-per-share tender offer

Medco sees powerful opportunity in generic biotech

Fri, 21 Nov 2008 16:06:00 GMT

By Lewis Krauskopf NEW YORK, Nov 21 (Reuters) - More than $34 billion worth of biotechnology medicines could become available as generics in the United States between 2013-2017 if lawmakers approve a path for their approval, Medco Health Solutions

Monsanto Beets Down Opposition

Fri, 21 Nov 2008 16:31:00 GMT

WILLAMETTE VALLEY, Ore.?The sugar beets growing in farmer Tim Winn?s fields do not look menacing. But other farmers in Oregon?s fertile Willamette Valley fear the beets could devastate their crops. Winn?s sugar beets have been

Biotech Executive John Collar Named Executive Director of the Colorado BioScience Association, Effective December 8

Fri, 21 Nov 2008 16:33:00 GMT

Following an extensive national search, John Collar, Chief Operating Officer of Westminster-based Matrilinex, has been named Executive Director of the Colorado BioScience Association (CBSA), effective December 8, 2008. A seasoned senior executive,

Imclone Systems Rises In Pre-Market After Eli Lilly Completes Cash Tender Offer

Fri, 21 Nov 2008 16:45:00 GMT

Imclone Systems (IMCL: ) climbed in pre-market trading, after Eli Lilly (LLY: ) completed its cash tender offer for the company. The stock was up 15 cents just after 8:45 am ET, advancing to $69.95. If pre-market gains hold, the stock will open at a

Determining gene expression on a single pair of microarrays

Fri, 21 Nov 2008 15:34:46 GMT

Background: In microarray experiments the numbers of replicates are often limited due to factors such as cost, availability of sample or poor hybridization. There are currently few choices for the analysis of a pair of microarrays where N=1 in each condition. In this paper, we demonstrate the effectiveness of a

Promacta gets FDA approval

Fri, 21 Nov 2008 13:46:20 GMT

The FDA has approved GlaxoSmithKline and Ligand Pharmaceuticals' Promacta (eltrombopag). The drug treats a rare immune condition called thrombocytopenia purpura, in which a patient's immune system attacks its own platelets. Promacta is the first oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic ITP.

Infinity gets $75M for cancer partnership

Fri, 21 Nov 2008 14:19:34 GMT

Infinity Pharmaceuticals is getting $75 million up-front in a partnership deal for the company's early-stage research. Purdue Pharma and affiliate Mundipharma are buying 4 million shares of Infinity for $45 million and may purchase an additional 2 million shares for $30 million. The partnership will advance Infinity's early-stage clinical and discovery

2008 NME approvals will surpass 2007

Fri, 21 Nov 2008 14:55:49 GMT

Last year was one of the bleakest on record in terms of new drug approvals. Only 18 new molecular entities were approved by the FDA--the lowest number since 1983. The first half of 2008 was nothing to brag about either, as the industry seemed to be destined to repeat

CombinatoRx restructures, axes staff--again

Fri, 21 Nov 2008 15:00:17 GMT

Despite starting the year off on a good note, CombinatoRx has announced its second round of restructuring and layoffs in less than a month. The Cambridge-based company has axed its workforce by another 30 employees, or 20 percent of its current staff--bringing total layoffs this month to 82, or 65 percent. This leaves the

More biotech bankruptcies on the horizon

Fri, 21 Nov 2008 15:46:44 GMT

Pharmalot reports that in the last month alone five developers

Vical cuts jobs, closes research facility

Fri, 21 Nov 2008 15:50:11 GMT

Many companies are trying to find ways to cut costs and preserve cash. The latest to announce restructuring and layoffs is San Diego-based Vical. In order to preserve capital and focus on its most advanced development programs, the biotech will reduce its workforce by 29 employees, approximately 20 percent of its total staff. Vical

[$$] Biotech Mailbag: Recap on GenVec (at RealMoney by TheStreet.com)

Fri, 21 Nov 2008 17:45:59 GMT

Lilly Completes Cash Tender Offer for ImClone Systems (PR Newswire)

Fri, 21 Nov 2008 18:24:00 GMT

Eli Lilly and Company and ImClone Systems Incorporated today announced the successful completion of the previously announced tender offer by Lilly's wholly-owned subsidiary, Alaska Acquisition Corporation, for all outstanding shares of ImClone at a price of $70.00 per share in

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing (PR Newswire)

Fri, 21 Nov 2008 18:43:00 GMT

Alseres Pharmaceuticals, Inc. , today announced that it has entered into a securities purchase agreement with Robert Gipson for the private placement of 543,478 shares of common stock of the Company, together with warrants to purchase 543,478 additional shares of common stock at an exercise price of $1.84 per share,

Lilly completes tender offer for ImClone (at MarketWatch)

Fri, 21 Nov 2008 18:44:32 GMT

Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union (PR Newswire)

Fri, 21 Nov 2008 19:25:00 GMT

Amgen today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Nplate in the European Union

ZymoGenetics says CEO Bruce Carter to retire (AP)

Fri, 21 Nov 2008 19:52:37 GMT

Drug developer ZymoGenetics Inc. said Friday Chief Executive Bruce Carter will retire Jan. 2 and be succeeded by President and Chief Scientific Officer Douglas

Moody's cuts Eli Lilly on ImClone acquisition (at MarketWatch)

Fri, 21 Nov 2008 20:15:46 GMT

Early Glance: Biotechnology companies (AP)

Fri, 21 Nov 2008 20:32:35 GMT

Tongjitang Chinese Medicines Company to Announce Third Quarter 2008 Financial Results on November 25, 2008 (Business Wire)

Fri, 21 Nov 2008 21:16:00 GMT

SHENZHEN, China----Tongjitang Chinese Medicines Company , a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it plans to announce its third quarter 2008 financial results before the market opens on Tuesday, November 25,

Amgen gets positive EU nod for blood-clot drug (AP)

Fri, 21 Nov 2008 21:28:15 GMT

Shares of Amgen Inc. rose Friday after the company said a European advisory committee is in favor of approving the biotechnology company's drug Nplate, which treats a rare blood-clotting

FDA Accepts Filing and Grants Priority Review for DX-88 for Hereditary Angioedema (Business Wire)

Fri, 21 Nov 2008 21:30:00 GMT

CAMBRIDGE, Mass.----Dyax Corp. announced today that the U.S. Food and Drug Administration has accepted for filing the Companyâ??s Biologics License Application for DX-88 for the treatment of acute attacks of hereditary angioedema and has designated the application for Priority

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 00:00:00 GMT

Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners

Fri, 21 Nov 2008 00:00:00 GMT

Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and i.v.Station(TM PENDING) Robots

Fri, 21 Nov 2008 00:00:00 GMT

Mediware Acquisition Adds 320 Pharmacy Facilities

Fri, 21 Nov 2008 00:00:00 GMT

Chemaphor Announces Proposed Private Placement

Fri, 21 Nov 2008 00:00:00 GMT

BioMimetic Therapeutics, Inc. Announces Patent Allowance from United States Patent and Trademark Office for PDGF Compositions Patent

Fri, 21 Nov 2008 00:00:00 GMT

Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies

Fri, 21 Nov 2008 00:00:00 GMT

SurModics, Vical, and CombinatoRx Lay Off Staff as Part of Restructuring Efforts

Fri, 21 Nov 2008 00:00:00 GMT

GSK and Neptunus Set to Form JV for Development of Flu Vaccines

Fri, 21 Nov 2008 00:00:00 GMT

Solvay Pays $25M Upfront for Rights to Depomed’s Pain Therapeutic

Fri, 21 Nov 2008 00:00:00 GMT

FDA Approval of GSK’s Promacta Triggers $2M Payment to Ligand

Fri, 21 Nov 2008 00:00:00 GMT

Oxygenated Tumor Cells Use Waste Product from Hypoxic Tumor Cells

Fri, 21 Nov 2008 00:00:00 GMT

Viagra Stays Behind EU Counters

Fri, 21 Nov 2008 13:49:08 GMT

Pfizer withdraws application to sell drug without prescription after it hits opposition from government

DuPont Opens Research & Development Center in India

Fri, 21 Nov 2008 11:37:01 GMT

DuPont Knowledge Center is First Integrated Knowledge Center Outside the United States. (PRWeb Nov 21, 2008)

Read the full story at

Cutting Edge Information: Cutting Edge Information Publishes Report Forecasting DPP-4 Inhibitor Sales to Increase 450% Through 2013

Fri, 21 Nov 2008 13:02:00 GMT

RESEARCH TRIANGLE PARK, NC (MARKET WIRE) A recently published therapeutic area forecasting report from pharmaceutical business intelligence leader Cutting Edge Information finds that DPP-4 inhibitors will quickly become the highest-grossing class within the diabetes market, even outpacing the long-acting

Chemaphor Inc.: Chemaphor Announces Proposed Private Placement

Fri, 21 Nov 2008 14:28:00 GMT

OTTAWA, CANADA (MARKET WIRE) Chemaphor Inc. (TSX VENTURE: CFR), a biotechnology research and development company today announced plans to seek financing of approximately $1 million, subject to demand for subscriptions, by way of a non-brokered equity private placement. The definitive terms, total amount and pricing of the private

Empire Genomics signs 2 deals

Fri, 21 Nov 2008 09:46:04 GMT

Two new partnerships are expected to boost contracts at a Buffalo life sciences

Study: N.C. leads in biosciences growth

Fri, 21 Nov 2008 13:51:41 GMT

North Carolina’s biotechnology industry, boosted by more than $1 billion in state investments, is growing at a much faster clip than biotech sectors in other states, according to a study by the N.C. Biotechnology

McCall gets top post at state title group

Fri, 21 Nov 2008 15:24:17 GMT

Alan McCall has been elected president of the Florida Land Title Association.

Survey: Economic woes shake Texas workers’ confidence

Fri, 21 Nov 2008 16:15:32 GMT

Texas employee confidence in the economy started to wane in October, according to the monthly Spherion Corp. Employment

Safety fears derail late-stage Amgen cancer trial

Fri, 21 Nov 2008 10:32:00 GMT

Amgen has been dealt a serious blow to its hopes to develop new cancer therapies. Researchers for Amgen and Takeda suspended enrollment in a late-stage trial for motesanib after tracking a higher death rate among patients taking the oncology

Oncolytics Biotech gets 30th US patent

Fri, 21 Nov 2008 10:37:00 GMT

Oncolytics Biotech Inc. has been granted its 30th US Patent, No. 7,452,723, entitled 'Methods for Preventing Reovirus Recognition for the treatment of Cellular Proliferative Disorders.' The allowed claims relate to kits comprised of reovirus and

(11/3) Cephalon obtains FDA approval for wider use of Treanda

Fri, 21 Nov 2008 10:41:00 GMT

Cephalon, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during

(11/4) Genentech submits sBLA for Avastin for previously treated glioblastoma

Fri, 21 Nov 2008 10:41:00 GMT

Genentech, Inc. announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If

DELL ALLIANCE FOR ROLLING OUT VOICE BIOMETRICS TO THE FINANCE INDUSTRY

Fri, 21 Nov 2008 10:53:00 GMT

Voice Commerce secures alliance with Dell Industry Solutions for the configuration and distribution of Voice Transact voice biometrics for the financial industry Dell Industry Solutions Group (ISG) has announced an alliance to work with Voice

'Unprecedented' Biotech Bankruptcies Erupt Amid Finance Crisis

Fri, 21 Nov 2008 11:06:00 GMT

Bloomberg reports: The global economic crisis has cut funding for biotechnology companies to the lowest level in a decade, triggering bankruptcies and threatening development of drugs based on biomedical breakthroughs. In the past month, at least

Research Consortium to Sequence Turkey Genome

Fri, 21 Nov 2008 11:39:00 GMT

The new upgrade to the Roche GS-FLX sequencing system permits more than 1 million individual sequencing reads to be generated for each sequencing run with an average read length of 400 base pairs. The turkey genome will be assembled using

Top Biotech Short-Squeeze Plays

Fri, 21 Nov 2008 12:11:00 GMT

, VPHM , HPQ (Cramer's Pick) , PG , RCL , FWLT , POT , OSIP One industry that is expected to do well in a Barack Obama presidency is biotech. With the drop in the stock market bringing down all stocks, including the biotechs, short-squeeze

BRIEF-EU agency backs Amgen's Nplate

Fri, 21 Nov 2008 12:22:00 GMT

Extract not

Patient makes good recovery after bioengineered airway transplant

Fri, 21 Nov 2008 12:25:00 GMT

Extract not

Australian researchers map Kangaroo Genome

Fri, 21 Nov 2008 12:47:00 GMT

Australian researchers have launched what is said to be the first detailed map of the kangaroo genome, thus completing the first phase of the kangaroo genomics project. Researchers from the following organizations have built a framework to assemble

India approves UNESCOs center for biotech training

Fri, 21 Nov 2008 12:47:00 GMT

India?s Union Cabinet has given approval for establishing the ?UNESCO Regional Center for Training and Education in Biotechnology? at Haryana, a northwestern state in India. It will be launched with a revised budget of $20 million. The center

Biotech Mailbag: Recap on GenVec

Fri, 21 Nov 2008 12:48:00 GMT

Extract not

Research and Markets: Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics Focuses on Partnerships for Business, Product, Technology and Royalty Assets

Fri, 21 Nov 2008 12:50:00 GMT

DUBLIN, Ireland (Business Wire) -- Research and Markets (http://www.researchandmarkets.com/research/a8cb4b/product_and_asset) has announced the addition of the 'Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics' report to

Research and Markets: Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics Focuses on Partnerships for Business, Product, Technology and Royalty Assets

Fri, 21 Nov 2008 12:50:00 GMT

(BUSINESS WIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/a8cb4b/product_and_asset) has announced the addition of the 'Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics' report to their offering.

Research and Markets: Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics Focuses on Partnerships for Business, Product, Technology and Royalty Assets

Fri, 21 Nov 2008 12:56:00 GMT

DUBLIN, Ireland--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/a8cb4b/product_and_asset The Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and

AnaSpec Signs Distribution Agreement with Shanghai Universal Biotech Company

Fri, 21 Nov 2008 13:12:00 GMT

AnaSpec and have announced a non-exclusive distributor agreement that will allow to distribute AnaSpec?s catalog and custom products throughout China. AnaSpec?s Director of Sales & Marketing, Violeta Rajkovska, noted, ?AnaSpec is pleased to

Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America

Fri, 21 Nov 2008 13:17:00 GMT

BRIEF-EU agency backs Amgen's Nplate

Fri, 21 Nov 2008 13:20:00 GMT

LONDON, Nov 21 (Reuters) - Amgen:The following are recommendations issued on Friday by a committee at the European Medicines Agency: * EU agency backs Amgen's blood platelet booster Nplate * EU agency backs Novartis blood pressure drug Rasilez HCT *

DEFRA plans secret GM trial sites

Fri, 21 Nov 2008 13:24:00 GMT

The locations of genetically modified crop trials will be kept secret in the future to prevent protesters from wrecking the trial sites, DEFRA has announced. Almost all of the 54 GM crop trials conducted since 2000 have been vandalised because

DEFRA responds to secret GM crop trial claims

Fri, 21 Nov 2008 13:25:00 GMT

DEFRA has said it cannot confirm reports suggesting that the government intends to conduct future genetically modified crop trials in secret. The reports claimed that the government was considering a number of measures to prevent trials being wrecked

Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America

Fri, 21 Nov 2008 13:30:00 GMT

SAN DIEGO, Nov. 21 CA-Cyntellect,Inc. New hire brings over 20 years of commercial life sciences sales experience to Cyntellect SAN DIEGO, Nov. 21 /PRNewswire/ -- Cyntellect, a privately-held life sciences company leading the development

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 13:33:00 GMT

INDIANAPOLIS and New York, Nov. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY - News) and ImClone Systems Incorporated (Nasdaq: IMCL - News) today announced the successful completion of the previously announced tender offer by

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 13:33:00 GMT

/PRNewswire-FirstCall via COMTEX/ -- Eli Lilly and Company (LLY: LLY News, chart, profile, more Last: Delayed quote data Add to portfolio Analyst Create alert Insider Discuss Financials Sponsored by: , , ) and ImClone Systems Incorporated (IMCL:

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 13:34:00 GMT

INDIANAPOLIS and New York, Nov. 21 IN-Lilly-tender-offer INDIANAPOLIS and New York, Nov. 21 -- Eli Lilly and Company (NYSE: LLY) and ImClone Systems Incorporated (Nasdaq: IMCL) today announced the successful completion of the previously announced

Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America

Fri, 21 Nov 2008 13:36:00 GMT

New hire brings over 20 years of commercial life sciences sales experience to Cyntellect SAN DIEGO 'Andre's extensive sales and sales management experience in the life sciences research market, particularly in the cellular bioassay and analysis

Lilly Completes Cash Tender Offer for ImClone Systems

Fri, 21 Nov 2008 13:41:00 GMT

INDIANAPOLIS and New York, Nov. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and ImClone Systems Incorporated (Nasdaq: IMCL) today announced the successful completion of the previously announced tender offer by Lilly's

Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America

Fri, 21 Nov 2008 13:46:00 GMT

ZymoGenetics Announces Changes in Senior Management (Business Wire)

Fri, 21 Nov 2008 16:00:00 GMT

SEATTLE----ZymoGenetics, Inc. , announced today in accordance with the companyâ??s succession plan that the Board of Directors has promoted Douglas E. Williams, Ph.D., the companyâ??s President, to the position of CEO, effective January 2,

Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO (PR Newswire)

Fri, 21 Nov 2008 16:15:00 GMT

Intellect Neurosciences, Inc. , a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease released today the following Letter to Shareholders from

ZymoGenetics names new CEO (at MarketWatch)

Fri, 21 Nov 2008 16:23:26 GMT

Vical Announces Strategic Restructuring and Staff Reduction (PR Newswire)

Fri, 21 Nov 2008 16:30:00 GMT

Vical Incorporated today announced a strategic restructuring including a staff reduction of 29 employees, approximately 20% of the company's total workforce, and accelerated closure of a research

ZymoGenetics says CEO Bruce Carter to retire (AP)

Fri, 21 Nov 2008 17:23:17 GMT

Drug developer ZymoGenetics Inc. said Friday Chief Executive Bruce Carter will retire in early 2009 and be replaced by President and Chief Scientific Officer Douglas

ImClone Systems' New Manufacturing Facility Receives FDA Approval for ...

Fri, 21 Nov 2008 09:29:17 GMT

ImClone Systems Incorporated has received approval from the FDA for its state-of-the-art "BB50" manufacturing facility to manufacture multiple

Arrowhead Publishers Releases New Report Analyzing the Global Cancer Therapy Market

Fri, 21 Nov 2008 07:37:10 GMT

A New report from Arrowhead Publishers entitled Cancer Therapeutics: Market Insight and R&D Pipeline Analysis provides valuable insight into the global market for cancer therapies and developmental-stage therapies. (PRWeb Nov 21, 2008)

Read the full story at

Recordati S.p.A.: Recordati S.p.A. SUBMITS FILE FOR APPROVAL OF SILODOSIN TO THE EMEA

Fri, 21 Nov 2008 08:48:00 GMT

MILAN, ITALY (MARKET WIRE) RECORDATI SUBMITS FILE FOR APPROVAL OF SILODOSIN TO THE

OTI to roll out biometric-based voter cards for un-named African nation

Fri, 21 Nov 2008 06:52:00 GMT

Banner On Track Innovations has signed a contract with the Electoral Commission of an un-named African Country to implement the upgrade of the its permanent voter registry, including new biometric-based voter cards. The value of the initial contract

Genomic Health, Inc. Q3 2008 Earnings Call Transcript

Fri, 21 Nov 2008 08:46:00 GMT

Good afternoon. My name is John and I will be your conference operator today. At this time, I would like to welcome everyone to the third quarter Genomic Health conference call. All lines have been placed on mute to prevent any background noise.

FDA gets more than 17,000 comments on transgenic animals

Fri, 21 Nov 2008 09:01:00 GMT

Extract not

Genzyme gives here and abroad

Fri, 21 Nov 2008 09:02:00 GMT

MHT's Jim Connolly: Social network sites focus on niches, sports MHT reporter Efrain Viscarolasaga on NECN: Green tech brings jobs back to Mass. MHT Editor Doug Banks on NECN: Decoding the Gen Y workforce Related News FDA speeds up Genzyme?s

BRIEF: Biotech firm sells O.V. building

Fri, 21 Nov 2008 09:27:00 GMT

Extract not

Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human OATP1B1 (SLCO1B1)

Fri, 21 Nov 2008 09:36:00 GMT

Drug Metabolism and Disposition Fast Forward This Article Google Scholar Received for publication September 2, 2008. Revised November 13, 2008. Accepted for publication November 13, 2008. Evita van de Steeg 1, Cornelia M.M. van der Kruijssen 1,

Empire Genomics signs 2 deals

Fri, 21 Nov 2008 09:55:00 GMT

Empire Genomics LLC, which offers genetic tests for more than 200 ailments and diseases, signed an alliance with Strategic Medicine of Windber, Pa., to provide products and services for the personalized medicine market. Strategic Medicine provides

Addendum. Cytoprophet: a Cytoscape plug-in for protein and domain interaction networks inference

Fri, 21 Nov 2008 07:33:45 GMT

An additional reference is needed in the article Cytoprophet: a Cytoscape plug-in for protein and domain interaction networks inference. We include this reference as a matter of addendum.

Contact:

The Burkholderia Genome Database: facilitating flexible queries and comparative analyses

Fri, 21 Nov 2008 07:33:45 GMT

Summary: As the genome sequences of multiple strains of a given bacterial species are obtained, more generalized bacterial genome databases may be complemented by databases that are focused on providing more information geared for a distinct bacterial phylogenetic group and its associated research community. The Burkholderia Genome Database represents a

IPEP: an in silico tool to examine proteolytic peptides for mass spectrometry

Fri, 21 Nov 2008 07:33:45 GMT

Peptide-based proteomics supports identification and quantification as well as localization of post-translational modifications (PTMs) within proteins extracted from biological samples. The ‘bottom-up’ approach involves the digestion of proteins into peptide fragments that can be detected and sequenced with liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). A web-based application, iPEP,

GEOmetadb: powerful alternative search engine for the Gene Expression Omnibus

Fri, 21 Nov 2008 07:33:45 GMT

The NCBI Gene Expression Omnibus (GEO) represents the largest public repository of microarray data. However, finding data in GEO can be challenging. We have developed GEOmetadb in an attempt to make querying the GEO metadata both easier and more powerful. All GEO metadata records as well as the relationships between

mspire: mass spectrometry proteomics in Ruby

Fri, 21 Nov 2008 07:33:45 GMT

Summary: Mass spectrometry-based proteomics stands to gain from additional analysis of its data, but its large, complex datasets make demands on speed and memory usage requiring special consideration from scripting languages. The software library ‘mspire’—developed in the Ruby programming language—offers quick and memory-efficient readers for standard xml proteomics formats, converters

WAVECLOCK: wavelet analysis of circadian oscillation

Fri, 21 Nov 2008 07:33:45 GMT

Summary: Oscillations in mRNA and protein of circadian clock components can be continuously monitored in vitro using synchronized cell lines. These rhythms can be highly variable due to culture conditions and are non-stationary due to baseline trends, damping and drift in period length. We present a technique for characterizing the

Identifying differentially expressed subnetworks with MMG

Fri, 21 Nov 2008 07:33:45 GMT

Background: Mixture model on graphs (MMG) is a probabilistic model that integrates network topology with (gene, protein) expression data to predict the regulation state of genes and proteins. It is remarkably robust to missing data, a feature particularly important for its use in quantitative proteomics. A new implementation in C

FABSIM: a software for generating FST distributions with various ascertainment biases

Fri, 21 Nov 2008 07:33:44 GMT

Summary: We have developed a software that applies ascertainment bias on simulated DNA sequences and calculates F_ST on them, so they can be used to generate neutral distributions that are appropriate to test whether the genetic differentiation of a particular gene between populations is compatible with neutral evolution, or, on

QGene 4.0, an extensible Java QTL-analysis platform

Fri, 21 Nov 2008 07:33:44 GMT

Summary: Of many statistical methods developed to date for quantitative trait locus (QTL) analysis, only a limited subset are available in public software allowing their exploration, comparison and practical application by researchers. We have developed QGene 4.0, a plug-in platform that allows execution and comparison of a variety of modern

A flexible forward simulator for populations subject to selection and demography

Fri, 21 Nov 2008 07:33:44 GMT

Summary: This article introduces a new forward population genetic simulation program that can efficiently generate samples from populations with complex demographic histories under various models of natural selection. The program (SFS_CODE) is highly flexible, allowing the user to simulate realistic genomic regions with several loci evolving according to a variety

GSEA-SNP: applying gene set enrichment analysis to SNP data from genome-wide association studies

Fri, 21 Nov 2008 07:33:44 GMT

The power of genome-wide SNP association studies is limited, among others, by the large number of false positive test results. To provide a remedy, we combined SNP association analysis with the pathway-driven gene set enrichment analysis (GSEA), recently developed to facilitate handling of genome-wide gene expression data. The resulting GSEA-SNP

MSX-3D: a tool to validate 3D protein models using mass spectrometry

Fri, 21 Nov 2008 07:33:44 GMT

Motivation: The technique of chemical cross-linking followed by mass spectrometry has proven to bring valuable information about the protein structure and interactions between proteic subunits. It is an effective and efficient way to experimentally investigate some aspects of a protein structure when NMR and X-ray crystallography data are lacking.

Results: We